Charlotte Woodward Organ Transplant Discrimination Prevention Act
Summary
S.1782, the Charlotte Woodward Organ Transplant Discrimination Prevention Act, was reported favorably out of the Senate HELP Committee on June 17, 2026. The bill prohibits discrimination based on disability in organ transplant eligibility, requiring covered healthcare entities to make reasonable modifications. No direct funding is authorized; the impact is regulatory compliance for transplant hospitals and providers.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.1782 is a regulatory compliance bill, not a funding bill
- 2.Transplant hospitals and providers must adjust eligibility protocols
- 3.Bipartisan support increases likelihood of passage
Market Implications
The bill is neutral for healthcare sector stocks in the near term. No direct financial impact is authorized. Investors should monitor floor action and potential amendments. The regulatory burden is modest and unlikely to materially affect earnings for large-cap healthcare companies like UNH or JNJ.
Full Analysis
- What happened: On June 17, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered S.1782 to be reported favorably with an amendment. The bill, introduced by Sen. Moody (R-FL) with 21 cosponsors, now awaits floor action. It is a companion to H.R.1520 in the House. 2) Money trail: The bill does not authorize or appropriate any funding. It imposes a regulatory mandate on covered entities (hospitals, transplant centers, health care providers) to not discriminate on the basis of disability in organ transplant eligibility. 3) Structural winners and losers: The primary impact is on transplant hospitals and healthcare providers. HCA, UNH, and JNJ are affected as they operate or supply transplant services. The bill removes barriers for disabled individuals, potentially increasing the pool of eligible transplant candidates, which could drive modest volume growth for transplant-related drugs and services. 4) No real market data provided; analysis is based on legislative structure. 5) Timeline: The bill must pass the full Senate, then the House (companion H.R.1520 is also in committee), then be signed by the President. Given the bipartisan sponsorship (21 cosponsors including both parties), passage is plausible but not guaranteed.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Prohibition on discrimination based on disability in organ transplant eligibility criteria
Who must act
Covered entities including licensed health care providers, hospitals, nursing facilities, laboratories, and transplant hospitals
What happens
Mandates that transplant hospitals and providers cannot deny or delay organ transplants based on disability status; requires reasonable modifications to policies and practices for qualified individuals with disabilities
Stock impact
HCA operates a large network of hospitals and transplant centers; the bill imposes compliance and operational costs to adjust transplant eligibility protocols, but may increase patient volume for transplant services as barriers are removed
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Health Marketplace and Savings Accounts for All Act
Our Doctors First Act of 2026
Patients Deserve Price Tags Act
VA Mental Health Outreach and Engagement Act
H–1Bs for Physicians and the Healthcare Workforce Act
Train More Nurses Act
Improving Access to Medicare Coverage Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.